Home Polyoxomolybdate

Polyoxomolybdate (POM) nanoclusters with radiosensitizing and scintillating properties for low dose X-ray inducible radiation-radio dynamic therapy

2020-03-14 11:22:00

 


Debabrata Maiti, Jing Zhong, Zheng Zhang, Hailin Zhou, Saisai Xion, Ziliang Dong, Sarvendra Kumar, Zhuang Liu, and Kai  Yang


Compared to chemotherapy and surgery, radiotherapy (RT) using X-rays, gamma rays or an electron beam is still broadly applied for cancer treatment in clinical applications.1 Numerous RT clinical trials have revealed that using high dose X-rays could kill most of the cancer cells, but also cause side effects to the patients. Optical therapy including photodynamic therapy (PDT)3,4 and photothermal therapy (PTT)5,6 have been developed for the last two decades to decrease the side effects. However, the weak penetration of light limits the therapeutic efficiency of optical therapy of tumors in deeper tissue.7 Therefore, X-rays with high deep penetration are widely used compared with  NIR light. However, the side effects of RT are unavoidable. Certainly, they have been partially alleviated by advanced nanobiotechnology. During X-ray radiation therapy (X-RT), radiosensitizers produce Compton or photoelectrons which strike adjacent water or biomolecules to generate reactive oxygen species (ROS), breaking indirectly DNA strands.8 Owning to insufficient biomolecules near to the radiosensitizers, loss of Compton or photoelectrons is another drawback of X-RT along with the prime problem of side effects. Addressing the issue to minimize the side effects and to overcome the limitations of X-RT and PDT, the use of X-rays for X-ray inducible PDT (X-RDT) has become a promising technique for the treatment of malignant tumors in the last decade.9–11 X-RDT is an energy transduction process. The scintillator nanoparticles (SNPs) could convert the high energy X-rays into light to stimulate photosensitizers (PS) for generation of toxic reactive oxygen species (ROS) which irreversibly damage cancer cells.12–14 Nanomedicine containing ScNPs such as nanoparticles with high Z-elements or metal nanoclusters have been observed to be an effective methodology to enhance PDT efficacy under X-ray irradiation.15,16 In this paradigm, ScNPs combined with porphyrin or organic dye as photosensitizers are glaringly investigated in vitro and in vivo to kill cancer cells or to destroy solid tumors.17,18 Amusingly, low dose treatment is the major advantage of X-RDT, but it still faces a lack of radiosensitivity. In order to accomplish splendid therapeutic efficacy, Lin and co-workers have successfully designed a hafnium (Hf)–Ru based nanoscale metal-organic framework (MOF) for mitochondrial-targeted X-ray induced radiation and radio dynamic therapy (X-RT-RDT) under low dose X-ray irradiation.19 In the Hf–Ru based MOF, Hf could act as an X-ray scintillator, and transfer high energy X-rays into Qlight for the Ru-complex photosensitizer to produce singlet oxygen (1O2).  Additionally,  Hf as an X-ray radiosensitizer was capable of generating hydroxyl radicals from adjacent water molecules resulting in enhancement of RT efficacy. However, high quantum yield and long lifetime of the photosensitizers are the imperative properties for superior RDT efficacy.20 Recently, the Chen group has well designed a  metal-doped silicate nanosensitizer conjugated with an effective photosensitizer, rose Bengal (RB) as a new X-PDT agent which exhibited a significant inhibitory effect on tumor progression under low dose X-ray irradiation.21 In order to improve X-RT, radiosensitizers (RS) have been immensely used for X-ray irradiated auger therapy (AT) in which low energy auger electrons disrupt directly DNA strands.22–24 The main attracting advantage of X-ray irradiated auger therapy (AT) is the continues generation of auger electrons upon single dose X-ray irradiation, which is unlike the frequent use of X-rays in conventional RT.25

 

Hence, to address the effective efficacy for both X-RT by  Auger electrons and X-RDT by producing 1O2, X-ray inducible radiation and radio dynamic therapy (X-RRDT) could build a revolution in the entire discipline of cancer treatment. Several recent studies have reported the significant radiosensitizing and scintillating properties of octahedral molybdenum clusters under X-ray irradiation. Herein, we established the largest strawberry-shaped polyoxomolybdate nanoclusters (POMo NCs) which exhibited radiosensitizing features by producing auger electrons and scintillating properties upon X-ray irradiation. To date, investigations on POMo NCs as an X-RT agent and POMo NCs-photosensitizer based X-RDT agents for tumor destruction have not yet been studied. Meanwhile, rose Bengal (RB) as a photosensitizer is massively used in light-induced PDT due to  the generation of abundant 1O2 with high quantum yield.28–30 Therefore, the design of nanoformulations composed of POMo NCs as an X-ray radiosensitizer and X-ray scintillator with RB as a photosensitizer could be an advanced technique for X-RRDT    to combat cancer.

 

In this work, we successfully synthesized POMo NCs and RB loaded PEG functionalized chitosan (CS) nanoformulations (PEGylated POM@CS–RB) as X-ray radiosensitizers and X-ray scintillators. Hollow structured CS for RB loading in their cavity to a large extent and simultaneously their cationic surface charge assisted to hold anionic POMo NCs firmly. Importantly, the remarkable radiosensitizing properties of the POMo NCs expedited X-ray induced RT as strongly evidenced by g-H2AX assay. Moreover, X-ray inducible excellent RDT efficacy by POMo NCs arose from their incredible scintillating properties in which the transduced energy stimulated RB to generate cytotoxic 1O2 as confirmed from the SOSG assay kit study extra and intracellularly. However, the mutual consequence of  RT and RDT from POMo@CS–RB leading to the damage of DNA which in turn resulted in the killing of cancer cells was successfully evidenced by both g-H2AX and live/dead cell co-staining assay. For instance, robust NIR absorbance of POMo NCs at 860 nm resulted in photoacoustic imaging (PA) guided X-ray inducible radiation and radio dynamic therapy (X-RRDT) in vivo. Finally, an in vivo study revealed the effective outcome in regression of the tumor growth without triggering side effects in major normal organs as demonstrated by hematoxylin and eosin (H&E) staining. However, the continuous production of auger electrons from POMo NCs under single-dose X-ray irradiation could be advantageous for low dose treatment. Additionally, the low dose treatment might protect the other normal organs from serious damage. Hence, our projected nanomaterials, PEGylated POMo@CS–RB could be successfully applied for clinical trials as X-RRDT agents for cancer treatment in the future.


Results and discussion
The detailed synthesis procedure for the formation of POMo nanoparticles (NPs), POMo NCs and hollow chitosan as well as the designing of PEGylated POMo@CS–RB have been discussed in the methods section. In brief, POMo nanoclusters (NCs) were obtained by the reduction of phosphomolybdic acid in a mild alkaline medium followed by cryodesiccation. POMo NCs were added to freshly prepared CS solution and then stirred for 24 h under dark conditions. After the removal of unloaded POMo, the yellowish blue solution was collected, yielding POMo loaded CS (POMo@CS) nano-formulation. Next, POMo@CS–RB was prepared by adding an RB solution in the POMo@CS solution. Polyethylene glycol (PEG) was used to modify the POMo@CS–RB nanoformulation to make it biocompatible. The overall design of PEGylated POMo@CS–RB and the plausible mechanism of auspicious mutual radiosensitization with scintillating properties for X-RRDT have been schematically demonstrated in Fig. 1. In short, upon X-ray irradiation, POMo NCs could constantly generate auger electrons to break DNA, improving RT efficacy. Meanwhile, POMo NCs could also transfer high energy X-rays into visible light to stimulate RB for the production of 1O2 which damaged DNA indirectly.


X-ray diffraction (XRD) patterns of POMo NCs were matched well with the previously reported articles31 (ESI,† Fig. S1). An interesting investigation on structural analysis by macro model-2 (MM-2) study revealed that strawberry-shaped POMo NCs composed of 652 Mo atoms with an overall size of 5.9 nm were structurally formed which was nicely corroborated by transmission electron microscope (TEM) images. To the best of our knowledge,  this was the largest  POMo cluster containing   163 Mo (Mo)3 units of three edge-sharing MoO6 octahedra and connecting to the central PO4 octahedron (Fig. 2a). This structure was formed following the kegging structure of PMo12O40.32 As shown in Fig. 2b and c, the crucially optimized strawberry structured POMo NC is shown by both stick-ball and space fill style, respectively. On controlled reduction of Mo(VI) to Mo(V), both oxidation states (VI/V) of Mo in POMo NCs persisted as determined by X-ray photoelectron spectroscopic (XPS) analysis (Fig. 2d). The full XPS spectrum of POMo NCs is presented in the ESI,† Fig. S2. Additionally, the intense peak at 670 nm was attributed to the metal to metal charge transfer between Mo(VI) and Mo(V), further assuring their simultaneous presence in the cluster (ESI,† Fig. S3). However, the sharp peak at 862 nm was ascribed to the charge transfer from oxygen to Mo(V), resulting in blue color. The monodispersed POMo NCs with an average size of 6 nm (histogram inset) were uniformly distributed on CS as shown by TEM images (Fig. 2e and f). Moreover, a uniform hollow structure in the CS was clearly observed by TEM images. The surface-modified POMo loaded CS (PEGylated POMo@CS) exhibited an average size of 80 nm (histogram inset, Fig. 2b), whereas, dynamic light scattering (DLS) measurement showed a Z-average of 106 nm with polydispersity index of 0.134 T 0.02 (ESI,† Fig. S4). Good distributions of molybdenum (Mo) and oxygen were successfully analyzed by TEM elemental mapping (Fig. 2c). The high Brauner Emmett Teller (BET) surface area and the Barret Joyner Halenda (BJH) pore size of PEGylated POMo@CS were measured to be B97 m2 g—1 and B50 nm, respectively, further ensuring the formation of hollow structured CS (ESI,† Fig. S5).

 

As expected, during RB loading, a large amount of RB was effectively loaded into the cavity of hollow CS. The successful loading of various concentrations of RB was examined from the characteristic UV-visible-NIR absorbance of RB at 530 nm (ESI,† Fig. S6a). The loading efficiency (POMo@CS: RB, w/w) was enhanced with increasing the concentration of RB and the utmost RB loading efficiency was calculated to be 68% (ESI,† Fig. S6b). The loaded RB in the POMo@CS–RB nanoformulation was very stable in different solutions including deionized water and phosphate buffer solution (PBS). Only less than 10% of RB could be released from the POMo@CS–RB nanoformulation (ESI,† Fig. S6c). Additionally, we also tested the stability of the POMo@CS–RB nanoformulation in different pH (pH 7.4 and 6.5) solutions. It was found that the size of the POMo@CS–RB nanoformulation exhibited no obvious change in different pH solutions, indicating good stability of the nanoformulation (ESI,† Fig. S7). Such a high amount of RB loading was due to the incorporation of dye molecules inside the cavity of hollow CS. However, the fine and firm orientation of the POMo NCs onto the CS was well explained from surface charge analysis as measured by zeta potential (ESI,† Fig. S8). The zeta potential of chitosan nanoparticles and POMo NCs was measured to be +31 and —9 mV, respectively. Therefore, the adequate distribution of anionic charged POMo NCs onto cationic CS was possible due to the effective ionic interaction between them. Nevertheless, after RB loading,  the positive surface charge of POMo@CS was decreased by 2 mV, further confirming RB loading in the cavity of hollow CS. Furthermore, the positive surface charge of +18  mV for  POMo@CS  was abruptly reduced to +6 mV after PEG modification. Almost neutral surface charge of PEGylated POMo@CS would enhance its mobility through the bloodstream during the animal experiment.
In order to evaluate the scintillating characteristics of POMo NCs upon X-ray irradiation, a photoluminescence (PL) study was assertively conducted (Fig. 2h). Bare POMo NCs exhibited no optical features. However, the RB showed a single strong broad emission centered at 566 nm upon excitation at 490 nm before and after X-ray treatment. A similar result was observed for RB loaded POMo@CS before X-ray irradiation. Interestingly, miniature observation revealed that two more peaks at 522 and 602 nm for RB loaded POMo@CS nanoparticles were intensified after X-ray treatment, while the most common peak of RB was at 566 nm at the same excitation energy. Here, we called these two peaks as phantom peaks because these appeared only for X-ray treated RB loaded POMo@CS. The appearance of the two phantom peaks could be explained as the occurrence of several redox reactions among the various reduced and oxidized states of RB which were produced at the excited triplet state of RB.33 It assumed that POMo NCs could act as an energy transducer.  Upon X-ray irradiation, POMo NCs could transfer incident high energy into visible light which could stimulate the RB in sequence to create its excited state. Since RB is a prominent photosensitizer to generate colossal 1O2 from molecular oxygen at its triplet excited state, it could be possible for a plentiful generation of 1O2 upon falling X-rays on RB loaded POMo NCs. The feasibility for the generation of singlet oxygen by POMo, RB or POMo@CS–RB was assessed by a single oxygen sensor green (SOSG) indicator. By measuring the fluorescence signal of SOSG, 1O2 is easily be detected in both extra and intracellular circumstances.34 However, in our experiment, 100 mM of SOSG was added to deionized water or an aqueous solution of  RB  or water-dispersed POMo or POMo@CS–RB at an RB and Mo concentration of 50 and 100 mg mL—1, respectively, and then irradiated with X-rays at 2 Gy. As shown in Fig. 2i, strong fluorescence intensity of SOSG for POMo@CS–RB treated solution was detected, while almost no response from other nanomaterials was observed. It could only be possible if POMo nanoclusters exhibited scintillating features under high energy electromagnetic radiation. Hence it was anticipated that upon X-ray irradiation, POMo nanoclusters might transfer the high energy into visible light which in turn activated RB to produce 1O2. Meanwhile, the same experiment was conducted at different X-ray doses in the range between  0  and  10  Gy and the production of singlet oxygen was quantified by measuring the fluorescence intensity of SOSG.  With increasing  X-ray doses, the fluorescence intensity of SOSG was sharply amplified for POMo@CS–RB, while negligible intensity was perceived for the rest of the tested samples (Fig. 2j). Furthermore, in order to determine whether hydroxyl radicals (●OH) as ROS were generated upon X-ray irradiation at a low dose, we carried out the p-aminophenyl fluorescein (APF) assay. AFP could react with  ●OH  resulting in a  strong fluorescence at  515  nm at an excitation wavelength of 490 nm.35,36 No prominent peak (data not shown) suggested that the excited triplet state of RB has proceeded importantly via the type II pathway.

 

In aid of the therapeutic performance of the synthesized X-RRDT nanoformulation, it is necessary to check its activity towards cells and the ability to localize to the site of the disease. Therefore, to image the intracellular distribution of the PEGylated POMo@CS–RB nanoformulation, we performed fluorescence imaging on 4T1 cells by using confocal laser scanning microscopy (CLSM) after incubation of the nanomaterial for 12 h  at 37   1C.   The cell nucleus was stained with   40,6-diamidino-2-phenyl indole  (DAPI)  (blue)  and the green fluorescence of the fluorescein isothiocyanate (FITC) conjugated POMo@CS–RB nanoformulation was observed in all the cells. The strong green fluorescence was spotted around the cell nucleus and preferentially distributed across the cytoplasm (Fig. 3a). The good internalization of the nanomaterials by the cells depended on endocytosis.

 

Henceforth, in vitro toxicity of the bare RB, PEGylated POMo@CS   and   POMo@CS–RB   nanoformulations towards 4T1 cells with and without X-ray irradiation was studied by 3-(4,5-dimethylthiazol-2-yl)-2,5diphenyltetrazolium bromide (MTT) assay. The control nanoparticles without X-ray treatment caused no toxicity to cells.  The cells were viable virtually up to 95% at a high concentration of both POMo (500 mg mL—1) and RB (200 mg mL—1) (ESI,† Fig. S9). Therefore, the results of the cell viability suggested that all nanoformulations were biocompatible to the 4T1 cells. In disparity, upon 2 Gy of
X-ray irradiation, the PEGylated POMo@CS nanoparticles caused a minute toxicity to the cells at low concentration of POMo NCs and cell viability was gradually dropped with increasing the concentration of POMo (Fig. 3d). This result specified that POMo NCs could perform as a fabulous X-ray radiosensitizer via X-ray inducible RT. However, RB induced no toxicity to the cell upon X-ray treatment. Importantly, at a very low concentration of both POMo and RB, the PEGylated POMo@CS–RB nanoformulation manifested a substantial death of 4T1 cells under a very low dose of X-ray irradiation (2 Gy) via X-ray inducible radiation and radio dynamic therapy (X-RRDT).

 

The hollow structure of CS could provide a novel nano- platform to load RB with a high content. In aid of the massive generation of extracellular 1O2, we hypothesized that POMo NCs might relay energy in the form of visible light to stimulate RB to produce 1O2 upon X-ray irradiation. To validate the effect in the detection of the ample generation of intracellular 1O2, singlet oxygen sensor green (SOSG) was used to detect 1O2. The cells incubated with PEGylated POMo@CS–RB nanoparticles and irradiated by X-rays exhibited strong green fluorescence signal. While minimal fluorescence signals were visualized for the other X-ray treated nanomaterials such as PBS, RB or PEGylated POMo@CS (Fig. 3b). Meanwhile, the fluorescence intensity of SOSG was detected by flow cytometry analysis. For X-ray treated PEGylated POMo@CS–RB nanoparticles, obtaining superior fluorescence intensity with diminished cell count confirmed that colossally generated 1O2 caused the death of the cells probably via X-ray inducible radio dynamic therapy (X-RDT) (Fig. 3c). However,  for  X-ray treated  RB  or  PEGylated  POMo@CS, no specious change was perceived in both the fluorescence intensities of SOSG and in cell count from X-ray irradiated PBS. Therefore, from in vitro data (Fig. 3d), we could speculate indirectly that the POMo@CS–RB nanoformulation could transfer the high energy into visible light which in turn stimulated the RB to produce 1O2 for killing cancer cells.

 

Encouraged by the radiosensitization effect of POMo NCs, we performed a DNA strands break immunofluorescence staining assay using phosphorylated g-H2AX, a sensitive protein biomarker to detect DNA damage induced by ionizing radiation. Upon X-ray irradiation at a dose of 2 Gy, red fluorescence of g-H2AX was alleged for both POMo and RB loaded POMo NCs, indicating the breakages of DNA double strands in the nuclei of the cells (Fig. 4a). POMo@CS–RB under X-ray irradiation would generate abundant ROS and decrease DNA damage repairability in the cytoplasm. Therefore, the POMo@CS–RB nanoformulation could significantly induce DNA damage. The results further confirmed that POMo nanoclusters could act as X-ray radiosensitizers which triggered DNA damage via X-ray inducible radiation therapy  (X-RT). Furthermore, strong red fluorescence was more intensified from the nuclei for POMo@CS–RB treated cells. In addition, no indication of fluorescence signal in PBS or RB treated cells at the same X-ray irradiation dose reversely supported the radiosensitization effect of POMo nanoclusters.

AA Blocks offers a comprehensive range of building blocks and specially designed scaffolds to support your R&D:

89-55-4

2-Fluoro-6-iodobenzoic acid

Catalog No.:AA003H84

CAS No.:111771-08-5 MDL No.:MFCD00042289

MF:C7H4FIO2 MW:266.0083

89-55-4

2-Bromo-5-fluorobenzoyl chloride

Catalog No.:AA007S5I

CAS No.:111771-13-2 MDL No.:MFCD03094438

MF:C7H3BrClFO MW:237.4535

89-55-4

Boc-alpha-methyl-L-phenylalanine

Catalog No.:AA003A4O

CAS No.:111771-58-5 MDL No.:MFCD02682284

MF:C15H21NO4 MW:279.3315

89-55-4

Ethyl 3-bromo-2,2-difluoropropanoate

Catalog No.:AA007S5F

CAS No.:111773-24-1 MDL No.:MFCD15144891

MF:C5H7BrF2O2 MW:217.0087

89-55-4

4-Allyloxyphenylboronic acid

Catalog No.:AA0081PZ

CAS No.:1117776-68-7 MDL No.:MFCD11103728

MF:C9H11BO3 MW:177.9928

89-55-4

2-(1,1-Difluoroethyl)pyrazine

Catalog No.:AA0090MY

CAS No.:111781-49-8 MDL No.:MFCD12546932

MF:C6H6F2N2 MW:144.1220

89-55-4

3-(Dimethylamino)-1-(2-pyrazinyl)-2-propen-1-one

Catalog No.:AA008ZFC

CAS No.:111781-53-4 MDL No.:MFCD02325230

MF:C9H11N3O MW:177.2031

89-55-4

2-(1H-Pyrazol-3-yl)pyrazine

Catalog No.:AA0078R4

CAS No.:111781-54-5 MDL No.:MFCD03618495

MF:C7H6N4 MW:146.1493

89-55-4

Piperazine, 2-(1H-pyrazol-3-yl)- (9CI)

Catalog No.:AA008VKH

CAS No.:111781-55-6 MDL No.:MFCD16140317

MF:C7H12N4 MW:152.1970

89-55-4

2-Pyridin-3-yl-piperazine

Catalog No.:AA0081OJ

CAS No.:111781-56-7 MDL No.:MFCD07373192

MF:C9H13N3 MW:163.2196

89-55-4

2-(Pyridin-4-yl)piperazine 2hcl

Catalog No.:AA00HC3Y

CAS No.:111781-57-8 MDL No.:MFCD07373195

MF:C9H13N3 MW:163.2196

89-55-4

2-amino-1-(4-chloro-2-fluorophenyl)ethan-1-one hydrochloride

Catalog No.:AA01BXCY

CAS No.:1117843-10-3 MDL No.:MFCD25978057

MF:C8H8Cl2FNO MW:224.0596

89-55-4

4-Chloro-2-MethylbenzaMide

Catalog No.:AA0093WJ

CAS No.:1117843-17-0 MDL No.:MFCD12922943

MF:C8H8ClNO MW:169.6082

89-55-4

Prinoxodan

Catalog No.:AA009U23

CAS No.:111786-07-3 MDL No.:MFCD00867136

MF:C13H13N4O2 MW:257.2679

89-55-4

N-(2-Aminoethyl)biotinamide

Catalog No.:AA0078QU

CAS No.:111790-37-5 MDL No.:MFCD09839905

MF:C12H22N4O2S MW:286.3937

89-55-4

(R)-3,3-Difluorocyclopentanamine hydrochloride

Catalog No.:AA00IKKC

CAS No.:1117936-64-7 MDL No.:MFCD23106014

MF:C5H10ClF2N MW:157.5894

89-55-4

(S)-(-)-3,3'-Dibromo-1,1'-bi-2-naphthol

Catalog No.:AA008SCG

CAS No.:111795-43-8 MDL No.:MFCD03093629

MF:C20H12Br2O2 MW:444.1161

89-55-4

(2E)-1-(3,4-dimethoxyphenyl)-3-(3,4,5-trimethoxyphenyl)prop-2-en-1-one

Catalog No.:AA00JUHO

CAS No.:111797-22-9 MDL No.:MFCD01060969

MF:C20H22O6 MW:358.3851

89-55-4

TRIMETHYLSILYL ISOCYANATE

Catalog No.:AA003V1P

CAS No.:1118-02-1 MDL No.:MFCD00001993

MF:C4H9NOSi MW:115.2059

89-55-4

TERT-BUTYLUREA

Catalog No.:AA003UJA

CAS No.:1118-12-3 MDL No.:MFCD00025448

MF:C5H12N2O MW:116.1616

89-55-4

N-(tert-Butyl)-2-methylbut-3-yn-2-amine

Catalog No.:AA007S1G

CAS No.:1118-17-8 MDL No.:MFCD02093662

MF:C9H17N MW:139.2380

89-55-4

N-(T-BUTYL)PROPANAMIDE

Catalog No.:AA009QXT

CAS No.:1118-32-7 MDL No.:MFCD00791235

MF:C7H15NO MW:129.2001

89-55-4

DI-N-PENTYLDICHLOROTIN

Catalog No.:AA008UR0

CAS No.:1118-42-9 MDL No.:MFCD00045150

MF:C10H22Cl2Sn MW:331.8887

89-55-4

Butyltrichlorostannane

Catalog No.:AA003OJM

CAS No.:1118-46-3 MDL No.:MFCD00000515

MF:C4H9Cl3Sn MW:282.1743

89-55-4

4,4-Dimethylpentanoic acid

Catalog No.:AA008SB4

CAS No.:1118-47-4 MDL No.:MFCD00101613

MF:C7H14O2 MW:130.1849

89-55-4

3-Aminocrotononitrile

Catalog No.:AA003IUO

CAS No.:1118-61-2 MDL No.:MFCD00008071

MF:C4H6N2 MW:82.1038

89-55-4

4-Amino-3-penten-2-one

Catalog No.:AA008UDR

CAS No.:1118-66-7 MDL No.:MFCD00043715

MF:C5H9NO MW:99.1311

89-55-4

N,N-Dimethylglycine

Catalog No.:AA003SID

CAS No.:1118-68-9 MDL No.:MFCD00004283

MF:C4H9NO2 MW:103.1198

89-55-4

N-Isopropylacetamide

Catalog No.:AA00840J

CAS No.:1118-69-0 MDL No.:MFCD00085718

MF:C5H11NO MW:101.1469

89-55-4

2,2,6,6-Tetramethyl-3,5-heptanedione

Catalog No.:AA0032TM

CAS No.:1118-71-4 MDL No.:MFCD00008848

MF:C11H20O2 MW:184.2753

89-55-4

Allyl acetoacetate

Catalog No.:AA007VB7

CAS No.:1118-84-9 MDL No.:MFCD00009811

MF:C7H10O3 MW:142.1525

89-55-4

L-Glutamic acid diethyl ester, HCl

Catalog No.:AA0034NN

CAS No.:1118-89-4 MDL No.:MFCD00012509

MF:C9H18ClNO4 MW:239.6965

89-55-4

L-2-Aminoadipic acid

Catalog No.:AA007VAY

CAS No.:1118-90-7 MDL No.:MFCD00002636

MF:C6H11NO4 MW:161.1558

89-55-4

N,N-Dimethyloctanamide

Catalog No.:AA0083YC

CAS No.:1118-92-9 MDL No.:MFCD00043763

MF:C10H21NO MW:171.2798

89-55-4

(S)-(-)-2-(a-(t-butyl)methanamine)-1H-benzimidazole

Catalog No.:AA008VJC

CAS No.:1118114-88-7 MDL No.:MFCD16038112

MF:C12H17N3 MW:203.2835

89-55-4

fenpyroximate

Catalog No.:AA0081NS

CAS No.:111812-58-9 MDL No.:MFCD00274596

MF:C24H27N3O4 MW:421.4889

89-55-4

BENZENE, 1-(BROMOMETHYL)-4-CYCLOHEXYL-

Catalog No.:AA009K7D

CAS No.:111818-33-8 MDL No.:MFCD11111736

MF:C13H17Br MW:253.1781

89-55-4

N-tert-Butyl-4-(chloromethyl)benzamide

Catalog No.:AA00948E

CAS No.:111818-35-0 MDL No.:MFCD02826188

MF:C12H16ClNO MW:225.7145

89-55-4

(S)-(-)-3-AMINO-1-HYDROXYPYRROLIDIN-2-ONE

Catalog No.:AA008SD2

CAS No.:111821-58-0 MDL No.:MFCD00078584

MF:C4H8N2O2 MW:116.1185

89-55-4

2-(4-Chlorophenoxy)benzaldehyde

Catalog No.:AA003ESU

CAS No.:111826-11-0 MDL No.:MFCD01568734

MF:C13H9ClO2 MW:232.6624

89-55-4

5,5-dimethyloxan-3-one

Catalog No.:AA0081NO

CAS No.:111826-28-9 MDL No.:MFCD24707102

MF:C7H12O2 MW:128.1690

89-55-4

4-Bromo-2,6-dichlorobenzaldehyde

Catalog No.:AA008Z5T

CAS No.:111829-72-2 MDL No.:MFCD11227147

MF:C7H3BrCl2O MW:253.9081

89-55-4

3-(4-tert-Butyl-benzoylamino)-propionic acid

Catalog No.:AA019IDH

CAS No.:111830-21-8 MDL No.:MFCD02936746

MF:C14H19NO3 MW:249.3056

89-55-4

2-Bromo-3-(n-benzylmethylamino)prop-1-ene

Catalog No.:AA008UP8

CAS No.:111831-90-4 MDL No.:MFCD00995624

MF:C11H14BrN MW:240.1396

89-55-4

N-(but-2-yn-1-yl)cyclohexanamine

Catalog No.:AA01C2PO

CAS No.:111831-93-7 MDL No.:MFCD00995890

MF:C10H17N MW:151.2487

89-55-4

PerindoprilDe-2-((S)-ethyl2-(Ethylamino)pentanoate)

Catalog No.:AA01DZJP

CAS No.:111836-22-7 MDL No.:

MF:C11H17NO3 MW:211.2576

89-55-4

2-Bromo-1-(5-chloro-2-methoxyphenyl)ethanone

Catalog No.:AA0078KA

CAS No.:111841-05-5 MDL No.:MFCD01793848

MF:C9H8BrClO2 MW:263.5156

89-55-4

UCPH 101

Catalog No.:AA007RI8

CAS No.:1118460-77-7 MDL No.:MFCD12913298

MF:C27H22N2O3 MW:422.4752

89-55-4

5-(pyridin-3-yl)pentan-2-amine

Catalog No.:AA01C2C1

CAS No.:111848-81-8 MDL No.:MFCD16301141

MF:C10H16N2 MW:164.2474

89-55-4

1-Ethyl-1h-imidazole-2-carbaldehyde

Catalog No.:AA008YYR

CAS No.:111851-98-0 MDL No.:MFCD07380875

MF:C6H8N2O MW:124.1405

89-55-4

4H-1,2,4-Triazol-4-amine,3,5-bis(methoxymethyl)-

Catalog No.:AA007RI5

CAS No.:111853-51-1 MDL No.:MFCD03789237

MF:C6H12N4O2 MW:172.1851

89-55-4

(1S)-1-{4-amino-5-[(1S)-1-hydroxyethyl]-4H-1,2,4-triazol-3-yl}ethan-1-ol

Catalog No.:AA00L5EK

CAS No.:111853-53-3 MDL No.:MFCD03837525

MF:C6H12N4O2 MW:172.1851

89-55-4

Bexagliflozin

Catalog No.:AA008TLT

CAS No.:1118567-05-7 MDL No.:MFCD28100944

MF:C24H29ClO7 MW:464.9359

89-55-4

H-D-2-NAL-CYS-TYR-D-TRP-LYS-VAL-CYS-2-NAL-NH2

Catalog No.:AA008USC

CAS No.:111857-96-6 MDL No.:MFCD00237258

MF:C63H73N11O9S2 MW:1192.4520

89-55-4

Benzyltrimethylammonium tribromide

Catalog No.:AA0034FQ

CAS No.:111865-47-5 MDL No.:MFCD00134423

MF:C10H16Br3N-- MW:389.9527

89-55-4

7-Deaza-ddG

Catalog No.:AA009202

CAS No.:111869-49-9 MDL No.:MFCD07778654

MF:C11H14N4O3 MW:250.2539

89-55-4

Halfenprox

Catalog No.:AA01FNWI

CAS No.:111872-58-3 MDL No.:

MF:C24H23BrF2O3 MW:477.3384

89-55-4

Butanenitrile,4-[(dimethylamino)dimethylsilyl]-

Catalog No.:AA007DDT

CAS No.:111873-32-6 MDL No.:MFCD05663912

MF:C8H18N2Si MW:170.3274

89-55-4

8-iodocubane-1-carboxylic acid

Catalog No.:AA01EIKG

CAS No.:111873-46-2 MDL No.:MFCD30723376

MF:C9H7IO2 MW:274.0552

89-55-4

5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid,7-[[(2-amino-4-thiazolyl)(methoxyimino)acetyl]amino]-3-[[[4-(2-carboxyethyl)-2-thiazolyl]thio]methyl]-8-oxo-, [6R-[6a,7b(Z)]]-

Catalog No.:AA01CBP1

CAS No.:111874-09-0 MDL No.:

MF:C20H20N6O7S4 MW:584.6688

89-55-4

3-amino-1,2,3,4-tetrahydro-1,8-naphthyridin-2-one dihydrochloride

Catalog No.:AA01BHSS

CAS No.:1118751-87-3 MDL No.:MFCD26405780

MF:C8H11Cl2N3O MW:236.0984

89-55-4

3,5-Bis(bromomethyl)pyridine hydrobromide

Catalog No.:AA01AM95

CAS No.:1118754-56-5 MDL No.:MFCD27996064

MF:C7H8Br3N MW:345.8571

89-55-4

N-(2-aminophenyl)pyrrolidine-1-carboxamide

Catalog No.:AA019UQH

CAS No.:1118786-84-7 MDL No.:MFCD11857948

MF:C11H15N3O MW:205.2563

89-55-4

tert-Butyl 2-azaspiro[3.3]hept-6-ylcarbamate

Catalog No.:AA007DDD

CAS No.:1118786-85-8 MDL No.:MFCD11858159

MF:C11H20N2O2 MW:212.2887

89-55-4

2-(Boc-amino)-6-oxospiro[3.3]heptane

Catalog No.:AA008U0I

CAS No.:1118786-86-9 MDL No.:MFCD11858160

MF:C12H19NO3 MW:225.2842

89-55-4

3-(2-Aminoethyl)benzamide

Catalog No.:AA0097XW

CAS No.:1118786-88-1 MDL No.:MFCD11858180

MF:C9H12N2O MW:164.2044

89-55-4

4,6-Dimethoxypyrimidin-5-methylamine

Catalog No.:AA0094GY

CAS No.:1118786-90-5 MDL No.:MFCD11858183

MF:C7H11N3O2 MW:169.1811

89-55-4

2-Trifluoromethoxy-ethanesulfonyl chloride

Catalog No.:AA019C6Z

CAS No.:1118786-91-6 MDL No.:MFCD11858188

MF:C3H4ClF3O3S MW:212.5753

89-55-4

7-fluoro-2-oxo-1,2,3,4-tetrahydroquinoline-6-sulfonyl chloride

Catalog No.:AA019UHV

CAS No.:1118786-95-0 MDL No.:MFCD11857862

MF:C9H7ClFNO3S MW:263.6732

89-55-4

2-(3-methyl-4-nitrophenyl)-1,3,4-oxadiazole

Catalog No.:AA019LYB

CAS No.:1118786-96-1 MDL No.:MFCD11833085

MF:C9H7N3O3 MW:205.1702

89-55-4

5-[(methylsulfanyl)methyl]furan-2-carbaldehyde

Catalog No.:AA019UI3

CAS No.:1118786-97-2 MDL No.:MFCD11857865

MF:C7H8O2S MW:156.2022

89-55-4

2-([(2-Chlorophenyl)methyl]amino)propan-1-ol

Catalog No.:AA019UIF

CAS No.:1118787-00-0 MDL No.:MFCD11840121

MF:C10H14ClNO MW:199.6773

89-55-4

5-carbamoyl-1H-pyrrole-3-carboxylic acid

Catalog No.:AA019UIN

CAS No.:1118787-01-1 MDL No.:MFCD11840126

MF:C6H6N2O3 MW:154.1234

89-55-4

2-(3-Aminophenyl)-6-ethyl-3,4-dihydropyrimidin-4-one

Catalog No.:AA018SBN

CAS No.:1118787-02-2 MDL No.:MFCD11840130

MF:C12H13N3O MW:215.2511

89-55-4

(E)-N-[1-(5-Phenylthiophen-2-yl)ethylidene]hydroxylamine

Catalog No.:AA019UKG

CAS No.:1118787-04-4 MDL No.:MFCD11857877

MF:C12H11NOS MW:217.2868

89-55-4

N-(3-tert-Butyl-3-azabicyclo[3.2.1]octan-8-ylidene)hydroxylamine

Catalog No.:AA01EJL2

CAS No.:1118787-09-9 MDL No.:MFCD13806385

MF:C11H20N2O MW:196.2893

89-55-4

4-chloro-5-nitro-1H-pyrrole-2-carboxylic acid

Catalog No.:AA019UKT

CAS No.:1118787-10-2 MDL No.:MFCD11840132

MF:C5H3ClN2O4 MW:190.5413

89-55-4

6-cyclopropyl-2-(methylsulfanyl)pyrimidine-4-carboxylic acid

Catalog No.:AA019UL5

CAS No.:1118787-11-3 MDL No.:MFCD11857887

MF:C9H10N2O2S MW:210.2529

89-55-4

[4-methyl-6-oxo-2-(pyridin-3-yl)-1H-pyrimidin-5-yl]acetic acid

Catalog No.:AA018SBR

CAS No.:1118787-12-4 MDL No.:MFCD11839729

MF:C12H11N3O3 MW:245.2340

89-55-4

5-methyl-4-(pyrrolidine-1-sulfonyl)furan-2-carboxylic acid

Catalog No.:AA019UM8

CAS No.:1118787-13-5 MDL No.:MFCD11857894

MF:C10H13NO5S MW:259.2789

89-55-4

3-Methyl-1H-pyrazolo[3,4-b]pyridine-5-carboxylic acid

Catalog No.:AA00HC45

CAS No.:1118787-14-6 MDL No.:MFCD11857900

MF:C8H7N3O2 MW:177.1601

89-55-4

3-(3-methoxyphenyl)-2-(5-methyl-1H-1,2,3,4-tetrazol-1-yl)propanoic acid

Catalog No.:AA019UNG

CAS No.:1118787-15-7 MDL No.:MFCD11857906

MF:C12H14N4O3 MW:262.2646

89-55-4

3-(4-fluorophenyl)-2-(5-methyl-1,2,3,4-tetrazol-1-yl)propanoic acid

Catalog No.:AA018SBI

CAS No.:1118787-16-8 MDL No.:MFCD11857907

MF:C11H11FN4O2 MW:250.2290

89-55-4

3-(3-fluorophenyl)-2-(5-methyl-1H-1,2,3,4-tetrazol-1-yl)propanoic acid

Catalog No.:AA019UOA

CAS No.:1118787-20-4 MDL No.:MFCD11857919

MF:C11H11FN4O2 MW:250.2290